These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1352 related articles for article (PubMed ID: 11152019)

  • 1. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP; Plosker GL
    Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC
    AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
    Jarvis B; Faulds D
    Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir: a review of its clinical potential in patients with HIV infection.
    Hervey PS; Perry CM
    Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
    Barry M; Mulcahy F; Merry C; Gibbons S; Back D
    Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delavirdine: clinical pharmacokinetics and drug interactions.
    Tran JQ; Gerber JG; Kerr BM
    Clin Pharmacokinet; 2001; 40(3):207-26. PubMed ID: 11327199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
    Conway B
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S130-4. PubMed ID: 10860897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
    Bhana N; Ormrod D; Perry CM; Figgitt DP
    Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.
    Been-Tiktak AM; Boucher CA; Brun-Vezinet F; Joly V; Mulder JW; Jost J; Cooper DA; Moroni M; Gatell JM; Staszewski S; Colebunders R; Stewart GJ; Hawkins DA; Johnson MA; Parkin JM; Kennedy DH; Hoy JF; Borleffs JC
    Int J Antimicrob Agents; 1999 Jan; 11(1):13-21. PubMed ID: 10075273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelfinavir: an update on its use in HIV infection.
    Bardsley-Elliot A; Plosker GL
    Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
    Fletcher CV; Acosta EP; Cheng H; Haubrich R; Fischl M; Raasch R; Mills C; Hu XJ; Katzenstein D; Remmel RP; Gulick RM;
    AIDS; 2000 Nov; 14(16):2495-501. PubMed ID: 11101060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.